JelloX Biotech Leads Research in 3D Cancer Pathology as NCI Explores Potential
SAN FRANCISCO, Dec. 3, 2022 /PRNewswire/ -- JelloX Biotech is celebrating a robust year of research and product development milestones while showcasing the potential for 3D imaging and AI to be the future of cancer pathology. Presently, most cancer diagnosis is done through thinly sliced physical biopsies. Though widespread, the amount...
Lakeshore Acquisition Corp I Shareholders Approve Business Combination with ProSomnus
SAN FRANCISCO, Dec. 3, 2022 /PRNewswire/ -- Lakeshore Acquisition I Corp. (Nasdaq: LAAA) ("Lakeshore") today announced that its shareholders have approved all proposals related to the previously announced business combination (the "Business Combination") with ProSomnus Holdings, Inc. ("ProSomnus") at a special meeting of shareholders held on December 2, 2022. Approximately 92.4% of the votes cast at the meeting on...
FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) ANNOUNCES $5 MILLION GIFT TO ADVANCE CLINICAL TRIALS IN RARE NEURODEVELOPMENTAL DISORDERS
The Center at Rush University Will Be Directed By Dr. Elizabeth Berry-Kravis MIAMI, Dec. 3, 2022 /PRNewswire/ -- The Foundation for Angelman Syndrome Therapeutics (FAST) announced today a $5 million gift to establish the new clinical trial and translational research effort for rare neurodevelopmental disorders, a first-of-its-kind flagship center to be directed by...
Epiprotect reduces the cost for treatment of hard to heal leg ulcers with 83%
LINKÖPING, Sweden, Dec. 3, 2022 /PRNewswire/ -- A compilation of data from patients treated at S2Clinic during the period 2019-2022 showed that the cost of treatment of these patients was reduced by approximately 83% compared to conventional treatment. The treatment with Epiprotect also resulted fully healed wounds in 100 % of the cases. 9 patients with a total of...
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
CEO Lance Kawaguchi Drives Effort & Brings Compelling Personal Story to Global Battle Against Cancer NEW YORK, Dec. 3, 2022 /PRNewswire/ -- Cure Brain Cancer Foundation CEO Lance Kawaguchi rang the bell to open trading on the Nasdaq stock exchange on Friday morning, December 2. The Foundation announced the establishment of an independent U.S. affiliate that will widely increase...
Sirolimus Coated Balloon in BTK Treatment makes a bold presence at VEITH 2022 – Lights up NY Times Square, NASDAQ
TAMPA, Fla., Dec. 2, 2022 /PRNewswire/ -- VEITH 2022 witnessed a surge of supporting clinical data for Sirolimus Coated Balloon in the treatment of Below-the-Knee (BTK) disease. Concept Medical Inc. hosted a lunch symposium titled 'Sirolimus Coated Balloon in PAD Treatment: Choice of The Future' which explored the utility of Sirolimus Coated...
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
JERSEY CITY, N.J. and SHANGHAI, Dec. 2, 2022 /PRNewswire/ -- Focus-X Therapeutics (referred to here as "Focus-X"), a nuclide drug company that was invested in and incubated by Viva Biotech, successfully reached an acquisition agreement with Full-Life Technologies Co., Ltd. (referred to here as "Full-Life"). Under the terms of the acquisition, Full-Life will acquire Focus-X for US$245 million, including an...
Qilu Pharmaceutical Releases Latest Results of QL1706 plus Chemotherapy +/- Bevacizumab for the Treatment of Non-Small Cell Lung Cancer in the Phase II Study at ESMO Asia Congress 2022
JINAN, China, Dec. 2, 2022 /PRNewswire/ -- Qilu Pharmaceutical, one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures, and distributes both finished formulations and Active Pharmaceutical Ingredients, announced that the results of the phase II study evaluating QL1706 plus chemotherapy +/- bevacizumab for the treatment of non-small cell lung cancer (NSCLC) were released on...
Waterdrop Inc. to Report Third Quarter 2022 Financial Results on December 6, 2022
BEIJING, Dec. 2, 2022 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2022, before U.S. markets open on Tuesday, December 6, 2022. Waterdrop's management team...
Parnell Pharmaceuticals Holdings Ltd Announces Proposed Rights Offering
SYDNEY, Dec. 2, 2022 /PRNewswire/ -- Parnell Pharmaceuticals Holdings Ltd (OTC Pink® Open Market: PARNF) ("Parnell") announced its intention to raise US$4.0 million through a backstopped rights offering at no charge (the "Rights Offering") for qualifying shareholders of record as of December 6, 2022 (the "Record Date"). The Rights Offering will be fully backstopped by existing investors DW Healthcare...
